

New classification of liver biopsy assessment for fibrosis before and after treatment

Hepatology

65, 1438-1450

DOI: [10.1002/hep.29009](https://doi.org/10.1002/hep.29009)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | On beyond staging and grading: Liver biopsy evaluation in a posttreatment world. <i>Hepatology</i> , 2017, 65, 1432-1434. | 3.6 | 8 |
| 3 | Histopathological evaluation of liver fibrosis and cirrhosis regression. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 302-307. | 4.5 | 90 |
| 4 | Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak <i>œstable</i> patients on anti-HBV therapy. <i>Scientific Reports</i> , 2018, 8, 2989. | 1.6 | 25 |
| 5 | Are we any closer to treating liver fibrosis (and if no, why not)? <i>Journal of Digestive Diseases</i> , 2018, 19, 118-126. | 0.7 | 9 |
| 6 | Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. <i>International Journal of Infectious Diseases</i> , 2018, 67, 58-64. | 1.5 | 6 |
| 7 | Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. <i>Modern Pathology</i> , 2018, 31, 1191-1200. | 2.9 | 37 |
| 8 | Platelets [™] increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. <i>Hepatology International</i> , 2018, 12, 237-243. | 1.9 | 14 |
| 9 | Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 15-22. | 1.4 | 44 |
| 10 | Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 503-510. | 1.4 | 24 |
| 11 | Longitudinal monitoring of liver stiffness by acoustic radiation force impulse imaging in patients with chronic hepatitis B receiving entecavir. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 227-236. | 0.7 | 2 |
| 12 | Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. <i>Hepatology Research</i> , 2018, 48, E283-E290. | 1.8 | 14 |
| 13 | Regression of HCV cirrhosis: Time will tell. <i>Hepatology</i> , 2018, 67, 1651-1653. | 3.6 | 13 |
| 14 | Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1391-1400. | 1.6 | 22 |
| 15 | Deep learning enables automated scoring of liver fibrosis stages. <i>Scientific Reports</i> , 2018, 8, 16016. | 1.6 | 81 |
| 16 | Acute-on-chronic liver failure 2018: a need for (urgent) liver biopsy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 565-573. | 1.4 | 10 |
| 17 | Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. <i>Modern Pathology</i> , 2018, 31, 1567-1577. | 2.9 | 11 |
| 18 | Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 61-69. | 1.4 | 17 |
| 20 | Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after achieving sustained virologic response for hepatitis C virus infection. <i>Oncology Letters</i> , 2019, 18, 1458-1466. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 21 | Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment. <i>Journal of Viral Hepatitis</i> , 2019, 26, 50-58. | 1.0 | 3 |
| 22 | Pathology and natural history of organ fibrosis. <i>Current Opinion in Pharmacology</i> , 2019, 49, 82-89. | 1.7 | 20 |
| 23 | Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. <i>Journal of Digestive Diseases</i> , 2019, 20, 467-475. | 0.7 | 6 |
| 24 | SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies. <i>Hepatology International</i> , 2019, 13, 501-509. | 1.9 | 7 |
| 25 | Dynamics of elastin in liver fibrosis: Accumulates late during progression and degrades slowly in regression. <i>Journal of Cellular Physiology</i> , 2019, 234, 22613-22622. | 2.0 | 25 |
| 26 | On-treatment changes of serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy. <i>Journal of Medical Virology</i> , 2019, 91, 1499-1509. | 2.5 | 3 |
| 27 | Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. <i>Clinica Chimica Acta</i> , 2019, 493, 92-97. | 0.5 | 18 |
| 28 | Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development. <i>Frontiers in Genetics</i> , 2019, 10, 305. | 1.1 | 26 |
| 29 | Locostatin Alleviates Liver Fibrosis Induced by Carbon Tetrachloride in Mice. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2570-2580. | 1.1 | 9 |
| 30 | Multitranscriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression independent of etiology. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G744-G754. | 1.6 | 20 |
| 31 | Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628. | 1.6 | 4 |
| 32 | Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. <i>Journal of Viral Hepatitis</i> , 2019, 26, 576-585. | 1.0 | 19 |
| 33 | Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 6632-6641. | 1.2 | 7 |
| 34 | Improved quantitative assessment of HBV-associated liver fibrosis using second-harmonic generation microscopy with feature selection. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 12-20. | 0.7 | 5 |
| 35 | Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126. | 6.1 | 27 |
| 36 | Utility of glutamine synthetase immunohistochemistry in identifying features of regressed cirrhosis. <i>Modern Pathology</i> , 2020, 33, 448-455. | 2.9 | 8 |
| 37 | EPA plus DHA improves survival related to a decrease of injury after extended liver ischemia in Sprague-Dawley rats. <i>Annals of Hepatology</i> , 2020, 19, 172-178. | 0.6 | 2 |
| 38 | Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges. <i>BioMed Research International</i> , 2020, 2020, 1-7. | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 39 | Regression of liver fibrosis: evidence and challenges. Chinese Medical Journal, 2020, 133, 1696-1702. | 0.9 | 27 |
| 40 | An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. Diagnostics, 2020, 10, 643. | 1.3 | 12 |
| 41 | Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis. Hepatology, 2020, 72, 729-741. | 3.6 | 111 |
| 42 | Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 2582-2591.e6. | 2.4 | 57 |
| 43 | Consensus on the diagnosis and treatment of hepatic fibrosis (2019). Journal of Digestive Diseases, 2020, 21, 127-138. | 0.7 | 17 |
| 44 | Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial. Contemporary Clinical Trials Communications, 2020, 19, 100601. | 0.5 | 6 |
| 45 | Utility and accuracy of transient elastography in determining liver fibrosis: a case-control study. European Journal of Pediatrics, 2020, 179, 671-677. | 1.3 | 11 |
| 46 | Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition). Journal of Integrative Medicine, 2020, 18, 203-213. | 1.4 | 22 |
| 47 | Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. Abdominal Radiology, 2021, 46, 1947-1957. | 1.0 | 11 |
| 48 | Pathology of Hepatitis B Virus (HBV) Infection and HBV-Related Hepatocellular Carcinoma. , 2021, , 99-122. | | 0 |
| 49 | Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease. Indian Journal of Pathology and Microbiology, 2021, 64, 104. | 0.1 | 4 |
| 50 | Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. Clinical and Molecular Hepatology, 2021, 27, 44-57. | 4.5 | 38 |
| 51 | Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy. World Journal of Gastroenterology, 2021, 27, 404-415. | 1.4 | 7 |
| 52 | Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatology International, 2021, 15, 611-620. | 1.9 | 7 |
| 53 | Evolution of the liver biopsy and its future. Translational Gastroenterology and Hepatology, 2021, 6, 20-20. | 1.5 | 18 |
| 54 | Second-harmonic generation (SHG) microscopy and hepatic venous pressure gradient-based validation of a novel histological staging system for alcoholic hepatitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 493-506. | 1.4 | 0 |
| 55 | Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis. American Journal of Clinical Pathology, 2021, 156, 802-809. | 0.4 | 2 |
| 56 | Evaluation of HCV-related liver fibrosis post-successful DAA therapy. Egyptian Liver Journal, 2021, 11, . | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 57 | A comparative study of cirrhosis sub-staging using the Laennec system, Beijing classification, and morphometry. <i>Modern Pathology</i> , 2021, 34, 2175-2182. | 2.9 | 5 |
| 58 | Guidelines for Prevention and Treatment of Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000. | 0.7 | 22 |
| 59 | SERS diagnosis of liver fibrosis in the early stage based on gold nanostar liver targeting tags. <i>Biomaterials Science</i> , 2021, 9, 5035-5044. | 2.6 | 12 |
| 61 | Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients. <i>PLoS ONE</i> , 2020, 15, e0239624. | 1.1 | 5 |
| 62 | Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-8. | 0.7 | 11 |
| 63 | Inter-observer Variability in Histomorphological Evaluation of Non-neoplastic Liver Biopsy Tissue and Impact of Clinical Information on Final Diagnosis in Shahid Beheshti University of Medical Sciences Affiliated Hospitals. , 2019, 14, 243-251. | | 5 |
| 64 | Quantification of Liver Fibrosis—A Comparative Study. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 447. | 1.3 | 27 |
| 65 | Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2018, 24, 4272-4280. | 1.4 | 4 |
| 66 | Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 419-427. | 1.2 | 6 |
| 67 | Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-7. | 0.7 | 8 |
| 69 | Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment. <i>China CDC Weekly</i> , 2020, 2, 596-600. | 1.0 | 3 |
| 70 | Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 547-554. | 0.8 | 0 |
| 71 | Advances in the diagnosis and treatment of viral hepatitis B and C in China. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, 379-380. | 0.9 | 0 |
| 72 | Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study. <i>Hepatology</i> , 2022, 75, 1373-1385. | 3.6 | 17 |
| 73 | Letter to the editor: Spontaneous regression of cirrhosis: A paradigm shift in our understanding of the natural history of NASH. <i>Hepatology</i> , 2022, 76, E1-E2. | 3.6 | 0 |
| 74 | Histological assessment based on liver biopsy: the value and challenges in NASH drug development. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1200-1209. | 2.8 | 9 |
| 75 | Combination antiretroviral therapy is associated with reduction in liver fibrosis scores in patients with HIV and HBV co-infection. <i>AIDS Research and Therapy</i> , 2021, 18, 98. | 0.7 | 6 |
| 86 | Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis. <i>Histology and Histopathology</i> , 2020, 35, 1309-1318. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 87 | Traditional Chinese medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via YAP/TAZ signaling. <i>Histology and Histopathology</i> , 2021, , 18373. | 0.5 | 1 |
| 88 | Features of fibrosis regression abound in non-cirrhotic patients with resected hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0267474. | 1.1 | 1 |
| 90 | Core Pathology Patterns in Medical Liver Specimens. , 2022, , 1-64. | | 0 |
| 91 | Fibrosis regression following hepatitis C antiviral therapy. <i>World Journal of Hepatology</i> , 2022, 14, 1120-1130. | 0.8 | 5 |
| 92 | Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. <i>Journal of Hepatology</i> , 2022, 77, 1399-1409. | 1.8 | 41 |
| 93 | Preoperative aspartate aminotransferase to albumin ratio correlates with tumor characteristics and predicts outcome of hepatocellular carcinoma patients after curative hepatectomy: a multicenter study. <i>BMC Surgery</i> , 2022, 22, . | 0.6 | 2 |
| 94 | Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease. <i>Hepatology International</i> , 2022, 16, 1052-1063. | 1.9 | 2 |
| 95 | Radiomics nomograms based on R2* mapping and clinical biomarkers for staging of liver fibrosis in patients with chronic hepatitis B: a single-center retrospective study. <i>European Radiology</i> , 2023, 33, 1653-1667. | 2.3 | 3 |
| 96 | Concept of Further Decompensation and Recompensation. , 2022, , 523-535. | | 1 |
| 97 | Construction of a prediction model for chronic HBV-associated hepatocellular carcinoma based on ultrasound radiomics. <i>Journal of Radiation Research and Applied Sciences</i> , 2022, 15, 100487. | 0.7 | 1 |
| 98 | Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. <i>Gut Microbes</i> , 2023, 15, . | 4.3 | 16 |
| 100 | The hepatoprotective effect of aspirin on carbon tetrachloride-induced hepatic fibrosis via inhibition of TGF β 1 pathway and pro-inflammatory cytokines IL1 β and COX2 in rats. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, . | | 1 |
| 101 | Hepatitis Due to Hepatotropic Viruses. , 2024, , 402-447. | | 0 |
| 102 | Quantitative image-based collagen structural features predict the reversibility of hepatitis C virus-induced liver fibrosis post antiviral therapies. <i>Scientific Reports</i> , 2023, 13, . | 1.6 | 1 |
| 113 | Digital pathology for nonalcoholic steatohepatitis assessment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2024, 21, 57-69. | 8.2 | 1 |